The European Genomic Medicine Consortium (EGMEDC)

Accelerating the Clinical Translation of CRISPR and Genetic Medicines Across Europe

Who we are

The European CRISPR Medicine Consortium (EGMEDC) is a pan-European, non-profit initiative convened by CRISPR Medicine News (CMN).

------

Our Mission

Our mission is to unite and empower clinical, academic, regulatory, and industry stakeholders to advance the development and delivery of CRISPR-based and related genetic therapies across Europe.

By aligning these efforts, we aim to establish a coordinated, ethical, and sustainable ecosystem for the clinical translation of genomic medicines - ensuring timely, safe, and equitable access for patients.

------

Strategic Aims

• Clinical Coordination and Implementation: Aligning cross-border trials, data sharing, and long-term monitoring (CMN Trial Database).
• Infrastructure Mapping and Creation: Connecting Europe's fragmented screening, gene and cell therapy capabilities and implementing joint clinical-grade tools and protocols.
• Policy & Regulation: Harmonizing ethics, health technology assessment (HTA), and European Medicines Agency (EMA) regulatory pathways.
• Access & Reimbursement: Supporting scalable and fair access models across EU member states.
• Industry + Public Collaboration: Bridging biotech, academic networks, national programs, and European initiatives.
• Annual Convening Power: Anchored by CRISPRMED - Europe’s leading genomic medicine conference in Copenhagen, where EGMEDC will have its annual meeting.

------

What’s Next

More details about our founding members and strategic partnerships will be shared soon.

Join us as we together shape the future of genomic medicine in Europe.

"Learn - Innovate - Access"